10th TRANSPLANT ACADEMY
Friday 15 November 2013, Amsterdam

2013 is a year of celebrations and special occasions for Amsterdam. The 400th anniversary of its ring of canals (one of the world’s most unique urban landscapes), the 175th anniversary of the Artis Zoo (the Netherlands’ oldest and best-known zoo), the 125th anniversary of the Concertgebouw (the concert hall world-famous for its unique acoustics) or the 40th anniversary of the Van Gogh Museum (housing the world’s largest collection of his drawings, paintings and letters) are but a few of the many milestones that Amsterdam will celebrate this year.

Amsterdam is also where the European Headquarters of Teva will move to in 2013 – so what better place could there be to host the 10th anniversary edition of the Transplant Academy?

DESCARTES / ERA-EDTA and Teva Europe are conjunctly delighted to announce that the 10th Transplant Academy will take place on Friday 15 November in Amsterdam. An initiative of Teva Pharmaceuticals Europe, the Transplant Academy carries on a tradition of science focused presentations by a select panel of expert speakers complemented by hands-on interactive workshops.

The meeting will be chaired by Daniel Abramowicz, president of DESCARTES, a working group of ERA-EDTA dedicated to renal transplantation and that has the development of educational activities pertaining to renal transplantation as one of its core mission elements. DESCARTES stands for Developing Education Science and Care for Renal Transplantation in European States.

Chair: Daniel Abramowicz   Faculty: speaker panel to be announced soon
Topics* include:
● How do the Dutch do it? Living donation on the rise.
● Which way is best in ABO-incompatible transplantation?
● The key to a successful paired kidney exchange program.
● Why and when should a deceased or living donor be used in pre-emptive transplantation?

Workshops* will handle:
● The marginal living donor: what does ERBP recommend?
● When not to perform an ABO-incompatible transplantation.
● Altruistic donors for paired kidney exchange programs: inclusion/exclusion criteria.

Please contact teva@trevisolutions.eu or call +39 327 9062532 to inquire about possibilities to register. Formal invite to follow.

NOT YOUR STANDARD TRANSPLANT
“Which techniques can we use to improve transplant numbers and results”

DESCARTES / ERA-EDTA and Teva Europe are conjunctly delighted to announce that the 10th Transplant Academy will take place on Friday 15 November in Amsterdam.

An initiative of Teva Pharmaceuticals Europe, the Transplant Academy carries on a tradition of science focused presentations by a select panel of expert speakers complemented by hands-on interactive workshops.

The meeting will be chaired by Daniel Abramowicz, president of DESCARTES, a working group of ERA-EDTA dedicated to renal transplantation and that has the development of educational activities pertaining to renal transplantation as one of its core mission elements. DESCARTES stands for Developing Education Science and Care for Renal Transplantation in European States.

Chair: Daniel Abramowicz   Faculty: speaker panel to be announced soon
Topics* include:
● How do the Dutch do it? Living donation on the rise.
● Which way is best in ABO-incompatible transplantation?
● The key to a successful paired kidney exchange program.
● Why and when should a deceased or living donor be used in pre-emptive transplantation?

Workshops* will handle:
● The marginal living donor: what does ERBP recommend?
● When not to perform an ABO-incompatible transplantation.
● Altruistic donors for paired kidney exchange programs: inclusion/exclusion criteria.

Please contact teva@trevisolutions.eu or call +39 327 9062532 to inquire about possibilities to register. Formal invite to follow.

* working titles, tbc
A SHORT HISTORY OF THE TRANSPLANT ACADEMY
From East to West and Around Europe

When Ciclosporin was introduced in the market and it enabled more and more successful transplantations, it was still the time of “the cold war” and “the iron curtain” in Europe. Patients behind the iron curtain did not have access to this drug that would enable them to “start a new life” with a new organ.

In that time a Czech pharmaceutical company called Galena developed a ciclosporin product for patients in the then Eastern European countries. A first successful product was launched in 1990, an oral solution named Consupren. The well-known difficulties in bringing the molecule ciclosporin into a formulation that provides stable resorption led to the development of another ciclosporin product, the gel-based emulsion.

This product was approved by authorities as Equoral® and was brought to the market by IVAX (an American company that acquired Galena). Next, Equoral® came into the Teva family by the acquisition of IVAX. The Teva Transplant portfolio now consists of the current gold standard therapies tacrolimus (Tacni®), mmf (Myfenax®), and prednisone – and will have more products in the future.

Teva, as a leading global pharmaceutical company delivering both innovative and generic products throughout the world, not only started to build an increasing portfolio of branded transplant products. The increasing dedication to Transplantation is also apparent in the commitment to cooperate with the transplant community to progress transplant science and in concomitant scientific support.

Especially the annual Teva Transplant Academy has developed into an educational programme that is well respected. It delivers independent science and is organised in collaboration with medical societies like DESCARTES (ERA-EDTA) and ESOT.

The Teva Transplant Academy started in Prague, Czech Republic, in 2003 – Prague being the headquarters of Teva Czech Industries at the time. And in 2013 the Transplant Academy celebrates its 10th anniversary in Amsterdam, The Netherlands, where the headquarters of Teva Europe are situated.

Every Transplant Academy addresses an issue of special interest and it travels around Europe. The first one started with “Focus on early post-transplant events” and this year it is going to focus on “Not your standard transplant”, going into some of the issues related to “not ideal” donors and how to improve outcomes after these transplants.